Recent price performance snapshot

CME Group (CME) has drawn investor attention after recent trading, with the share price around $296.94 and mixed returns across different periods, including a negative move over the past month and a positive trend over the past 3 months.

For context, CME Group’s 1 month share price return of a 9.04% decline contrasts with a 10.11% share price gain year to date. The 5 year total shareholder return of 79.09% points to strong longer term compounding, suggesting recent momentum has cooled after a solid multi year run.

If you are weighing CME Group against other opportunities, this is a good moment to broaden your search and check out 20 top founder-led companies

With CME Group delivering positive multi year total returns, consistent revenue and net income growth, and trading only slightly below the average analyst price target, you have to ask: is this a genuine opening, or is the market already pricing in future growth?

Most Popular Narrative: 3.2% Undervalued

Against the last close at $296.94, the most followed narrative pegs CME Group’s fair value at about $306.86, with that gap hinging on specific growth and margin assumptions.

The ongoing global shift toward electronic trading, greater regulatory demands for transparency and standardized clearing, and a proven ability to grow non-transactional revenue (e.g., record market data revenue) position CME to capture a larger share of trading activity and support durable long-term earnings growth.

Read the complete narrative. Read the complete narrative.

Want to see what earnings mix and margin profile sit behind that fair value? The narrative leans on measured revenue expansion, thick profitability, and a premium future earnings multiple. Curious which assumptions really carry the model?

Result: Fair Value of $306.86 (UNDERVALUED)

However, there is still real execution risk if trading volumes soften in key futures contracts or if DeFi style platforms gradually chip away at market share.

Another Angle On Valuation

The narrative points to a 3.2% gap between the current $296.94 share price and a fair value of $306.86, suggesting mild undervaluation. Yet our DCF model points the other way, with an estimated future cash flow value of $245.27, which would frame the current price as overvalued instead. Which perspective aligns better with your expectations for CME Group’s cash generation and risk profile?

Next Steps

If this mix of moderate optimism and clear risks leaves you on the fence, take a closer look at the data and decide where you stand, starting with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

You have already put in the effort to understand CME Group, so do not stop short when a few focused screeners could surface alternatives that fit your style.

• Target potential mispricings by scanning for quality companies trading at appealing levels using the 63 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with prudent leverage and robust financial footing through the solid balance sheet and fundamentals stocks screener (39 results).
• Seek more stable income by reviewing companies offering strong yields and consistent payouts via the 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.